Correlation Between Icosavax and Inhibrx
Can any of the company-specific risk be diversified away by investing in both Icosavax and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Icosavax and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Icosavax and Inhibrx, you can compare the effects of market volatilities on Icosavax and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Icosavax with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Icosavax and Inhibrx.
Diversification Opportunities for Icosavax and Inhibrx
Pay attention - limited upside
The 3 months correlation between Icosavax and Inhibrx is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Icosavax and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Icosavax is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Icosavax are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Icosavax i.e., Icosavax and Inhibrx go up and down completely randomly.
Pair Corralation between Icosavax and Inhibrx
If you would invest (100.00) in Icosavax on December 29, 2024 and sell it today you would earn a total of 100.00 from holding Icosavax or generate -100.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
Icosavax vs. Inhibrx
Performance |
Timeline |
Icosavax |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Inhibrx |
Icosavax and Inhibrx Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Icosavax and Inhibrx
The main advantage of trading using opposite Icosavax and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Icosavax position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.Icosavax vs. Terns Pharmaceuticals | Icosavax vs. Amylyx Pharmaceuticals | Icosavax vs. Acumen Pharmaceuticals | Icosavax vs. Inozyme Pharma |
Inhibrx vs. Mirum Pharmaceuticals | Inhibrx vs. Rocket Pharmaceuticals | Inhibrx vs. Avidity Biosciences | Inhibrx vs. Uniqure NV |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Complementary Tools
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |